The role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients by Varga, Zoltán et al.
Int. J. Radiation Oncology Biol. Phys., Vol. 80, No. 4, pp. 1109–1116, 2011
Copyright  2011 Elsevier Inc.
Printed in the USA. All rights reserved
0360-3016/$–see front matter
jrobp.2010.03.044doi:10.1016/j.iCLINICAL INVESTIGATION Breast
ROLE OF SYSTEMIC THERAPY IN THE DEVELOPMENT OF LUNG SEQUELAE
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ConflicPurpose: To analyze the risk of radiogenic lung damage in breast cancer patients after conformal radiotherapy and
different forms of systemic treatment.
Methods and Materials: In 328 patients receiving sequential taxane-based chemotherapy, concomitant hormone
therapy (tamoxifen or aromatase inhibitors), or no adjuvant systemic therapy, symptomatic and asymptomatic
lung sequelae were prospectively evaluated via the detection of visible CTabnormalities, 3 months or 1 year after
the completion of the radiotherapy.
Results: Significant positive associations were detected between the development of both pneumonitis and fibrosis
of Grade 1 and patient age, ipsilateral mean lung dose, volume of the ipsilateral lung receiving 20 Gy, and irradi-
ation of the regional lymph nodes. In multivariate analysis, age and mean lung dose proved to be independent pre-
dictors of early (odds ratio [OR] = 1.035, 95% confidence interval [CI] 1.011–1.061 and OR = 1.113, 95% CI
1.049–1.181, respectively) and late (OR = 1.074, 95%CI 1.042–1.107 and OR = 1.207, 95%CI 1.124–1.295, respec-
tively) radiogenic lung damage, whereas the role of systemic therapy was significant in the development of Grade 1
lung fibrosis (p = 0.01). Among the various forms of systemic therapy, tamoxifen increased the risk of late lung se-
quelae (OR = 2.442, 95% CI 1.120–5.326, p = 0.025). No interaction was demonstrated between the administration
of systemic therapy and the other above-mentioned parameters as regards the risk of radiogenic lung damage.
Conclusions: Our analyses demonstrate the independent role of concomitant tamoxifen therapy in the
development of radiogenic lung fibrosis but do not suggest such an effect for the other modes of systemic
treatment.  2011 Elsevier Inc.
Radiation lung sequelae, Tamoxifen, Aromatase inhibitors, Taxanes.INTRODUCTION
The various forms of adjuvant therapy, including postopera-
tive irradiation and systemic therapy in breast cancer, con-
tribute to the decreasing mortality rate among the affected
population (1, 2). Adjuvant radiotherapy is a standard form
of treatment after breast-conserving surgery and is sometimes
also practised after mastectomy (3, 4). Nonetheless,
radiotherapy might cause long-term toxicity, such as
radiation-induced pneumonitis and fibrosis of the lung. Early
radiation-induced symptoms arise within 6 months after the
completion of radiotherapy and may later progress to
a chronic fibrotic status (5, 6). The incidence of radiation-
induced lung injury in breast cancer in different prospective
studies varies between 4.5% and 63% (7–15). Most
radiation pneumonitis and fibrosis are asymptomatic after
breast radiotherapy because of the relatively small
irradiated lung volume and low radiation dose. Even so, thet requests to: Zsuzsanna Kaha´n, M.D., Ph.D., Department
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1109prevention of radiation lung damage can be facilitated by
the identification of risk factors. Patient age, irradiated
volume of the lung, and the dose to it are clearly related to
early and late radiation damage (7, 9, 13–15). Our earlier
studies suggested the synergistic effect of lung dose with
age in patients older than 59 years (13).
For the postoperative treatment of breast cancer, interna-
tionally accepted guidelines exist, based on decades of clin-
ical experience (16, 17). Adjuvant systemic therapies
roughly halve the risk of death and contribute to local
control. The application of the various forms of endocrine
therapy or chemotherapy is more and more individualized
on the basis of the features of the tumor. The different
hormone therapy options are widely applied in hormone
receptor–positive breast cancers, either during or after
radiotherapy (16, 17). Tamoxifen, a competitive antagonist
of 17-b-estradiol, is used in both premenopausal and
postmenopausal patients, whereas the aromatase inhibitorsAcknowledgment—The authors thank Dr. Zsuzsanna Va´rnay for
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exclusively to postmenopausal patients. Numerous
chemotherapy regimens are used, and because the inclusion
of paclitaxel or docetaxel has significantly improved
efficacy, these taxane-based regimens now represent the stan-
dard of care in high-risk cases. In some reports, the simulta-
neous administration of tamoxifen during radiotherapy was
associated with the development of early or late radiation
lung damage (18–20), whereas no such relationship was
observed in other studies (9, 14, 21–23). No similar data
have been published to date regarding the use of aromatase
inhibitors during breast radiotherapy, except for one small
study (24). Nevertheless, Azria et al. (25) and Ozsahin
et al. (26) reported that the increased level of subcutaneous
fibrosis after radiotherapy in the randomized COHORT study
was not related to the simultaneously administered letrozole
therapy but rather to the low radiation-induced CD8 lympho-
cyte apoptosis (RILA) status of the patient (25, 26).
Concomitantly administered radiochemotherapy leads to
unacceptable acute and late lung toxicity (27–29). The
sequential use of chemotherapy including the taxane-based
regimens and irradiation does not seem to increase the risk
of lung injury (9, 11, 30).METHODS AND MATERIALS
The study was approved by the institutional review board of the
University of Szeged, and all enrolled patients gave their written in-
formed consent to participate in the study.Study population
Between November 2001–August 2004 and January 2006–May
2008, patients after curative surgery for breast cancer who required
radiotherapy were recruited at our department. Patients with prior
malignancy, pulmonary or autoimmune disease, or any other signif-
icant health problem, or who were receiving glucocorticoid therapy,
were excluded. The initial surgery was either mastectomy or breast-
conserving surgery, with sentinel lymph node biopsy or/and axillary
lymph node dissection. The patient and tumor characteristics are
presented in Table 1. Data were collected on smoking habits, with
participants categorized as past or present smokers or nonsmokers.Systemic treatment
Depending on the systemic treatment administered, the subjects
were subdivided postoperatively into four groups: 79 patients com-
pleted a taxane-based perioperative chemotherapy regimen (involv-
ing either docetaxel at a dose of 75 mg/m2 or paclitaxel at a dose of
175 or 200 mg/m2 in combination or sequentially with doxorubicin
at a dose of 60 mg/m2 or epirubicin at a dose of 75 mg/m2 and cy-
clophosphamide at a dose of 800 mg/m2) for$4 weeks before radio-
therapy (taxane group); 159 patients received adjuvant hormonal
therapy: tamoxifen, 20 mg/day, n = 77, or aromatase inhibitor (anas-
trozole, 1 mg/day, or letrozole, 2.5 mg/day) n = 82, started $2
weeks before the initiation of radiotherapy (tamoxifen and aroma-
tase inhibitor groups, respectively); and a further 90 patients (control
group) received no systemic medication before, during, or after the
radiotherapy.Radiotherapy
Computed tomography–based three-dimensional treatment plan-
ning and conformal radiotherapy was in all cases performed with the
patient in a supine position. All relevant technical details have been
published previously (13, 31). Briefly, CT images were acquired at
every 1 cm throughout the entire planning volume. The target
volume and organs at risk were contoured on the CT slices in the
radiotherapy planning system. The planning target volume
coverage was analyzed via the dose–volume histograms and
isodose visualization. Local (operated breast or chest wall) or
locoregional (the former together with coverage of any of the
following regions: axillary, supraclavicular, and internal
mammary lymph nodes) radiotherapy was chosen according to the
local protocol. A standard technique of irradiation was used to
cover the operated breast/chest wall and the internal mammary
lymph nodes with tangential fields, and from January 2005,
individually weighted 6- or 15-MV segmental fields were
superimposed on the tangential fields, using a multileaf collimator
for better dose homogeneity. The axillary and supraclavicular
nodes were irradiated with a direct photon field. The tumor bed
boost was delivered with either 6-MV photon or 8–15-MeV
electron fields. The radiation dose to the remaining breast
parenchyma/chest wall and to the lymph nodes, if indicated, was
25  2 Gy (prescribed to the mean of the planning target
volume); a tumor bed boost of 5–8  2 Gy was delivered when
necessary. Organ-at-risk constraints were used as previously de-
scribed, and the volume of the ipsilateral lung receiving more than
20 Gy (V20Gy) and the mean lung dose (MLD) were registered for
the purpose of this study (13, 31). Radiotherapy was delivered
with a linear accelerator in 5 fractions per week. Although the
technical background changed due to modernization in 2005, the
use of different planning and positioning systems or field-shaping
techniques did not influence the radiotherapy protocol significantly.
Evaluation of radiogenic lung damage
At 3 months and at 1 year after the completion of the radiotherapy,
clinical follow-up visits with special attention to pulmonary symp-
toms (fever, cough, and dyspnea) and diagnostic CT examinations
were performed. The CT scans at these stages were compared
with those provided for radiotherapy planning purposes according
to the accepted criteria (13). The evaluation was performed indepen-
dently by two physicians. The categories of Grade 1 pneumonitis or
Grade 1 fibrosis were used to describe the new appearance of inflam-
matory or fibrotic abnormalities in the radiation fields at the two time
points, regardless of whether the patient simultaneously developed
specific clinical signs and symptoms, according to the Common
Toxicity Criteria version 2.0. The CT examinations were not per-
formed 1 year after the radiotherapy in 15 cases because of the pro-
gression of the breast cancer or some other disease (n = 9), the lack
of compliance of the patient (n = 5), or a car accident (n = 1).
Statistical analysis
The various patient- and radiotherapy-related characteristics were
examined in the four groups of patients according to the presence or
absence of radiogenic lung damage by univariate statistical
methods, with one-way analysis of variance and c2 test being
used for continuous and categoric variables, respectively. The rela-
tionships of age and MLD were examined by analysis of covariance.
The associations between severity of radiation lung damage and
patient age were analyzed by independent-samples t test.
Logistic regression models were applied to examine the potential
risk factors for the occurrence of early and late CT changes with or
Radiation lung sequelae and systemic therapy in breast cancer d Z. VARGA et al. 1111without clinical symptoms. First, binary univariate logistic regres-
sion models were used separately, followed by the multivariate lo-
gistic regression model to examine the joint effects and
interactions. A stepwise procedure was used with a likelihood ratio
test. The software program SPSS 15.0 for Windows (SPSS, Chi-
cago, IL) was applied for statistical analysis.
RESULTS
Altogether 328 patients were enrolled into the study. The
main characteristics of the patients who participated are
listed in Table 1. The mean (SE) age of the study popu-
lation was 59.4  0.6 years (range, 28.2–87.1 years). The
vast majority (96%) of the tumors were invasive, and two
thirds were invasive ductal cancers. All the patients in the
hormone therapy groups had estrogen and/or progesterone
receptor–positive tumors. The HER2 status did not differ
significantly in the different groups. The distribution of
the irradiated volumes among the four groups, together
with other radiotherapy-related data, is presented in Table
1. The rate of locoregional radiotherapy, and as a conse-
quence the MLD and V20Gy, were significantly higher in
the taxane group (p < 0.001) (Table 1). The proportion of
past or present smokers was the highest in the tamoxifen
group (p = 0.052). Radiation pneumonitis of Grade 1 was
found in 41.8% of the patients, and 5.8% had mild clinical
symptoms. Grade 1 radiation fibrosis developed in 30.4% of
the patients; none of them had symptoms. The incidence of
radiation pneumonitis or fibrosis did not exhibit significant
variations during the study.
The presence of early or late radiogenic lung damage was
compared with the various patient- and radiotherapy-related
characteristics (Tables 2 and 3). Highly significant associa-
tions were found between the presence of early or late radio-
genic lung changes and patient age, MLD, and V20Gy. There
was a weak negative correlation between age and MLD in the
overall study population (r =0.143, p = 0.009). Nodal irra-
diation favored lung damage (p = 0.017 at 3 months, and p <
0.001 at 1 year after the radiotherapy). One year after radio-
therapy, Grade 1 fibrosis was more frequent when mastec-
tomy had been performed (p < 0.001) (Table 3), thoughTable 1. Associations of the patient- and radiotherapy-related ch
of systemic t
Characteristic Control (n = 90) Taxane (n =
Age (y), mean  SE) 62.4  1.0 51.1  1.1
Irradiated volume
Breast 64 (71.1) 50 (63.3)
Chest wall 26 (28.9) 29 (36.7)
Irradiation of the regional lymph nodes
Yes 16 (17.8) 66 (83.5)
No 74 (82.2) 13 (16.5)
MLD (Gy), mean  SE 8.9  0.3 14.1  0.5
V20Gy (%), mean  SE 16.9  0.7 29.0  1.1
Smoking
Present or past smokers 38 (42.2) 29 (36.7)
Nonsmokers 52 (57.8) 50 (63.3)
Abbreviations: MLD = mean lung dose; V20Gy = volume of the ipsilat
Values are number (percentage) unless otherwise noted.this was probably a consequence of the higher frequency of
supraclavicular and axillary irradiation after mastectomy
than after tumor excision (49.6% vs. 32.6%, respectively,
p < 0.003). A past or present history of smoking did not in-
fluence the degree of radiogenic lung damage 3 months and
1 year after radiotherapy (Tables 2 and 3).
The incidence of Grade 1 pneumonitis or Grade 1 fibrosis
did not differ in the four treatment groups, but most cases of
symptomatic pneumonitis were observed in the tamoxifen
group (p = 0.076)) (Table 4). When the effect of patient
age on the radiogenic lung changes was analyzed in the dif-
ferent treatment groups, the patients with symptomatic pneu-
monitis in the tamoxifen group proved to be significantly
older than the patients without lung damage (p = 0.013)
(Fig. 1). A significant association was found between the
presence of Grade 1 pneumonitis and the presence of Grade
1 fibrosis (p < 0.001, McNemar test).Univariate analysis
To estimate the risks of pneumonitis or fibrosis, the effects
of patient age, MLD, and the different modes of systemic
treatment were first studied in binary univariate logistic re-
gression models. The risks of Grade 1 pneumonitis and Grade
1 fibrosis were increased 3 months and 1 year, respectively,
after radiotherapy, with odds ratio (OR) = 1.030 (95% confi-
dence interval [CI] 1.009–1.051, p = 0.004) and OR = 1.054
(95% CI 1.029–1.081, p < 0.001), respectively, for every 1-
year increase in the age of the patient. Significant positive as-
sociations were demonstrated between the risk of Grade 1
pneumonitis and MLD (OR = 1.080; 95% CI 1.027–1.135,
p = 0.003) and between the risk of Grade 1 fibrosis and
MLD (OR = 1.156; 95% CI 1.091–1.224, p < 0.001) for ev-
ery 1.0-Gy increase. Significant associations were not found
between the risks of early or late radiogenic lung damage and
the addition of systemic therapy (Table 4).Multivariate analysis
The joint effects of age, MLD, the systemic treatment, and
their interactions were examined in a multiple logisticaracteristics of the study population and the various forms
herapy
79) Tamoxifen (n = 77) Aromatase inhibitor (n = 82) p
56.6  1.2 66.3  0.9 <0.0001
0.449
46 (59.7) 55 (67.1)
31 (40.3) 27 (32.9)
<0.0001
22 (28.6) 22 (26.8)
55 (71.4) 60 (73.2)
10.7  0.5 10.0  0.4 <0.0001
21.1  1.3 19.7  1.0 <0.0001
0.052
38 (49.4) 24 (29.3)
39 (50.6) 58 (70.7)
eral lung receiving 20 Gy.
Table 2. Associations of patient- and radiotherapy-related characteristics of the study population and early radiation lung sequelae
Grade 1 pneumonitis
Characteristic No change (n = 191) Symptomatic (n = 19) p (vs. no change) Any (n = 137) p (vs. no change)
Age (y), mean  SE) 57.8  0.8 63.4  2.3 0.036 61.5  0.9 0.009
Irradiated volume 0.086 0.963
Breast 66 (34.6) 10 (52.6) 47 (34.3)
Chest wall 125 (65.4) 9 (47.4) 90 (65.7)
Irradiation of the regional lymph nodes 0.189 0.017
Yes 63 (33.0) 10 (52.6) 63 (46.0)
No 128 (67.0) 9 (47.4) 74 (54.0)
MLD (Gy), mean  SE 10.2  0.3 12.7  1.1 0.019 11.7  0.4 0.011
V20Gy (%), mean  SE 20.1  0.8 25.7  2.7 0.024 23.4  0.8 0.017
Smoking 0.509
Present or past smokers 78 (40.8) 5 (26.3) 0.232 51 (37.2)
Nonsmokers 113 (59.2) 14 (73.7) 86 (62.8)
Abbreviations as in Table 1.
Values are number (percentage) unless otherwise noted.
1112 I. J. Radiation Oncology d Biology d Physics Volume 80, Number 4, 2011regression model, using a stepwise algorithm. All three vari-
ables remained significant in the model (Table 5). Whereas
the risks of any radiation pneumonitis and that with symp-
toms and the administration of systemic therapy displayed
nonsignificant trends (p = 0.080 and p = 0.064, respectively),
the risk of fibrosis was significantly elevated by the adminis-
tration of systemic therapy (p = 0.001) or of tamoxifen (p =
0.025). The joint effects of age, MLD, and the systemic treat-
ment on the risk of radiation fibrosis are illustrated in Fig. 2.
Only the interaction of age and MLD remained significant in
the development of late CT abnormalities (OR = 1.006; 95%
CI 1.000–1.013, p = 0.050 with every 1-year increase in
patient age and every 1-Gy increase in MLD). No interaction
was detected for the various types of systemic therapy and the
dosimetric parameters, irrespective of whether the analysis
extended to the entire population or only to an older age
group.DISCUSSION
Based on a complex set of clinical data on 328 breast can-
cer patients, this analysis revealed that the concomitant
administration of tamoxifen with adjuvant radiotherapy inde-Table 3. Associations of patient- and radiotherapy-related characteris
Characteristic No change (n = 2
Age (y), mean  SE) 57.9  0.7
Irradiated volume
Breast 61 (28.0)
Chest wall 157 (72.0)
Irradiation of the regional lymph nodes
Yes 65 (29.8)
No 153 (70.2)
MLD (Gy), mean  SE 9.9  0.3
V20Gy (%), mean  SE 19.4  0.7
Smoking
Present or past smokers 92 (42.2)
Nonsmokers 126 (57.8)
Abbreviations as in Table 1.
Values are number (percentage) unless otherwise noted.pendently increases the risk of radiation lung fibrosis,
whereas the aromatase inhibitors and sequential taxane-
based chemotherapy have no such effect. We believe that
our findings of the advantages of conformal radiotherapy
and individualized adjuvant systemic therapy make a notable
contribution to the clarification of the discrepancy that has
long existed regarding the relation of systemic treatment
and radiation lung damage and indicate the need for the with-
drawal of tamoxifen during adjuvant radiotherapy.
Tamoxifen has been widely applied for the treatment of
breast cancer in the adjuvant setting, and its coadministration
with adjuvant radiotherapy has been the subject of numerous
studies (7, 9, 14, 18, 19, 22–24, 32). In some of these the
incidence of radiation lung complications did not differ
when tamoxifen was or was not administered
simultaneously with radiotherapy (7, 9, 14, 23, 24). The
negative results might have been due to the retrospective
nature of the analyses (14, 22), the underpowered study
populations (9, 21, 24), the limitation of the study endpoint
to pneumonitis (9), or the low sensitivity of the method of
follow-up (14, 22, 23). In other studies, the incidence of
radiogenic pulmonary fibrosis proved to be significantly
higher in the patients treated with tamoxifen (18–20). Thetics of the study population and the late radiation lung sequelae
18) Grade 1 fibrosis (n = 95) p
63.6  1.1 <0.001
<0.001
46 (48.4)
49 (51.6)
<0.001
51 (53.7)
44 (46.3)
12.6  0.4 <0.001
25.4  1.0 <0.001
0.157
32 (33.7)
63 (66.3)
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Radiation lung sequelae and systemic therapy in breast cancer d Z. VARGA et al. 1113first such trial was that of Bentzen et al. (18): in a randomized
study of 84 postmenopausal women, the risk of radiation fi-
brosis in the axillary and supraclavicular fields was doubled
when tamoxifen was coadministered with the radiotherapy.
Koc et al. (19) applied postoperative telecobalt irradiation
in 111 patients and observed that regular chest CTs revealed
lung fibrosis rates of 35% when tamoxifen was administered
during the radiotherapy vs. 13% when it was not. Huang et al.
(20) reported that tamoxifen therapy was an independent risk
factor of radiation lung fibrosis when coadministered during
electron-irradiation of the chest wall (OR = 3.35, p = 0.03).
These three studies did not involve the use of conformal
radiotherapy and could not include dose–volume histogram
data in the analysis. The strength of our study is that, besides
confirming tamoxifen as a risk factor in the development of
radiogenic lung fibrosis, it investigated the role of systemic
therapy independently of the simultaneous effects of dosi-
metric factors and age. These parameters can easily be taken
into consideration when deciding about the radiotherapy. Our
findings support and complement the well-demonstrated data
on the role of tamoxifen in the development of another form
of late radiogenic toxicity, subcutaneous fibrosis (25, 26, 32).
Our analysis has the limitation, however, that it does not take
into account the inherent radiosensitivity of the individual.
Such approaches have been suggested by the determination
of circulating transforming growth factor-b (TGF-b) (33–
35) or RILA (25, 26, 32) in breast cancer patients.
Transforming growth factor-b is a major participant in the
processes of wound healing and fibrosis, and the induction of
its synthesis may speed up the vicious cycle of chemotaxis
and the activation of neutrophils, T lymphocytes, monocytes,
and fibroblasts initiated by radiotherapy (36). Tamoxifen
stimulates the secretion of TGF-b by the fibroblasts, which
might serve as one explanation for the increased risk of radi-
ation lung damage when tamoxifen is coadministered with
radiotherapy. In the first 119 of our patients, we measured
TGF-b plasma levels before and during the radiotherapy, as
reported earlier (13). Although we found correlations be-
tween the variations in circulating TGF-b and both the lung
density changes and the development of symptomatic pneu-
monitis 3 months after the radiotherapy, no differences were
observed as concerns the type of systemic therapy (data not
shown). There could be many reasons for this finding. First,
the plasma levels of TGF-b probably do not represent the in
situ TGF-b concentrations with adequate sensitivity (37).
Second, it can not be excluded that the individual levels of
drug metabolic capacity (CYP2D6 polymorphism), which
determine the formation of the active metabolite of tamoxi-
fen, as recently evidenced by clinical data (38), also influence
the extent of TGF-b induction.
We tested whether another antiestrogen, toremifen, can in-
fluence the plasma TGF-b level. No significant change was
detected in 7 metastatic breast cancer patients after treatment
with toremifen (data not shown). Our results are consistent
with the findings of a pilot study on metastatic breast cancer
patients, whose TGF-b plasma levels were unchanged after
treatment with tamoxifen (35).
Fig. 1. Associations of Grade 1 pneumonitis and age (mean  SE) with the various forms of systemic therapy.
1114 I. J. Radiation Oncology d Biology d Physics Volume 80, Number 4, 2011The optimal sequencing of tamoxifen and radiotherapy has
not yet been established. Three retrospective clinical studies
were consistent in demonstrating no significant difference in
outcome in terms of local control, relapse-free survival, and
overall survival if tamoxifen was given concurrently or se-
quentially with radiotherapy (39). We beleive that, on the
basis of the increased risk of radiation fibrosis and the lack
of demonstrable therapeutic benefit if tamoxifen is used con-
comitantly with radiotherapy, their coadministration should
be avoided.
The use of third-generation aromatase inhibitors is cur-
rently the standard endocrine therapy for postmenopausal
women with hormone-dependent breast cancer (16). For
this reason, we set out to test the effects of anastrozole and
letrozole administered in conjunction with radiotherapy.
Although estrogen deprivation could in theory exert a disad-
vantageous effect on postirradiation tissue remodelling (40),
no change was observed in the risk of radiogenic lung se-
quelae. Our results accord with those of Azria and Ozsahin
(25, 26), who found no association between theTable 5. Multivariate analysis of the effects of age, MLD, and s
Grade 1 pneumonitis, symptomatic
Factor OR 95% CI p
Age 1.041 0.991–1.094 0.106 1
MLD 1.126 1.009–1.256 0.033 1
Systemic treatment 0.064
Taxane 0.465 0.066–3.268 0.442 0
Tamoxifen 2.775 0.746–10.323 0.128 1
Aromatase inhibitor 0.804 0.188–3.435 0.768 0
Abbreviations as in Tables 1 and 4.concomitant administration of letrozole with radiotherapy
and the development of subcutaneous fibrosis. As far as we
are aware, ours is the first well-powered study that has specif-
ically pointed to lung complications and the use of aromatase
inhibitors in the clinical radiotherapy setting.
The findings regarding the risk of radiation pneumonitis af-
ter chemotherapy are controversial. Radiation lung sequelae
were found to be more frequent in breast cancer patients
who received chemotherapy in some studies (19, 21),
whereas in others no difference was seen (14, 23). The
addition of taxanes to anthracyclin-based chemotherapy im-
proved the survival in early breast cancer (30), and their use
in clinical practice is universal. Early reports on the coadmin-
istration of paclitaxel with adjuvant radiotherapy suggested
an increased risk of lung sequelae (27–29), whereas in a
retrospective analysis of 189 breast cancer patients
treated with radiotherapy and 5-fluorouracil-doxorubicin-
cyclophosphamide chemotherapy, randomly with or without
paclitaxel, Yu et al. (30) found equally low incidences of radi-
ation pneumonitis and no difference between the two groupsystemic therapy on early and late radiogenic lung sequelae
Grade 1 pneumonitis, any Grade 1 fibrosis
OR 95% CI p OR 95% CI p
.035 1.011–1.061 0.005 1.074 1.042–1.107 0.001
.113 1.049–1.181 0.001 1.207 1.124–1.295 0.001
0.080 0.010
.674 0.309–1.470 0.322 0.750 0.294–1.915 0.548
.679 0.863–3.266 0.127 2.442 1.120–5.326 0.025
.955 0.504–1.806 0.887 0.765 0.359–1.632 0.488
Fig. 2. Risk of Grade 1 radiation fibrosis as indicated by multivariate logistic regression model including patient age, ra-
diation dose to the ipsilateral lung, and type of systemic treatment. Note that although in the model mean lung dose (MLD)
was a continuous variable, in the graph for delineation, the median mean lung dose value of 10 Gy was used as a threshold.
Radiation lung sequelae and systemic therapy in breast cancer d Z. VARGA et al. 1115(5% vs. 4.5%). In our study, the provision of chemotherapy in-
volving paclitaxel or docetaxel was not associated with
a higher risk of radiation pulmonary complications. In fact, de-
spite the significantly higher irradiated lung volumes, the inci-
dence of pulmonary toxicity was negligible. This finding can
be explained in terms of the significantly younger age in the
taxane group and is consistent with our results demonstrating
the greatest influence of age on lung complications (13).
Age is one of the most important risk factors of radiation
lung complications. Within the tamoxifen group, those pa-
tients who developed radiation pneumonitis were signifi-
cantly older than those who did not (Fig. 1). The question
arose as to whether tamoxifen treatment is in synergy withage, but our analysis did not support this. In the control and
aromatase inhibitor groups, the radiogenic lung changes
were not related to age, probably because of the lack of a sim-
ilarly broad range of age as in the tamoxifen group.CONCLUSIONS
The concomitant administration of tamoxifen with adju-
vant radiotherapy independently increases the risk of radia-
tion lung fibrosis, whereas the aromatase inhibitors and
sequential taxane-based chemotherapy exhibit no such effect.
Our results suggest that tamoxifen should not be adminis-
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